Arrowhead Pharmaceuticals (ARWR) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.04), Bloomberg Earnings reports. The company had revenue of $3.51 million during the quarter, compared to analyst estimates of $8.71 million. Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%.

Arrowhead Pharmaceuticals (NASDAQ ARWR) traded down $0.07 during trading on Friday, reaching $5.59. The company’s stock had a trading volume of 1,240,000 shares, compared to its average volume of 2,270,000. Arrowhead Pharmaceuticals has a one year low of $1.42 and a one year high of $6.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.63 and a current ratio of 3.63. The firm has a market capitalization of $413.12, a PE ratio of -11.89 and a beta of 2.52.

ARWR has been the topic of several analyst reports. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research note on Monday, November 27th. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. BidaskClub cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Cantor Fitzgerald set a $2.00 price objective on Arrowhead Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, December 12th. Finally, B. Riley initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, January 5th. They issued a “neutral” rating and a $3.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $3.13.

In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total value of $73,800.00. Following the sale, the chief operating officer now directly owns 948,356 shares in the company, valued at $3,499,433.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Arrowhead Pharmaceuticals (ARWR) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply